Prelude Therapeutics Inc PRLD
Prelude Therapeutics Inc (Nasdaq: PRLD) is an oncology drug developer. Its lead program, PRT12396, is in Phase 1 for polycythemia vera and myelofibrosis (JAK2V617F-mutant MPN). Its next catalyst on record is PRT13722: Prelude expects to initiate a Phase 1 trial of PRT13722 in patients with HR+/HER2- breast cancer in the fourth quarter of 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PRT13722 — Prelude expects to initiate a Phase 1 trial of PRT13722 in patients with HR+/HER2- breast cancer in the fourth quarter of 2026. (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PRT12396 (JAK2V617F mutant-selective inhibitor) | polycythemia vera; myelofibrosis | small molecule | Phase 1 |
| PRT13722 (KAT6A degrader) | HR+/HER2- breast cancer | small molecule | Pre-clinical |
| CALR-targeted degrader antibody conjugates | myeloproliferative neoplasms | antibody | Pre-clinical |
| SMARCA2/4 degrader payload DACs (with AbCellera) | solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Sep 10, 2026accepted FDA cleared IND for PRT13722 Phase 1 study in HR+ breast cancer patients, with enrollment anticipated to begin in fourth quarter 2026.
IND application clearance received; Phase 1 study of PRT13722 in patients with HR+/HER2- breast cancer anticipated to being enrolling in the fourth quarter.
Filing - Sep 10, 2026started Phase 1 dose escalation study of PRT13722 as monotherapy and in combinations expected to start enrolling in fourth quarter 2026.
Phase 1 study of PRT13722 in patients with HR+/HER2- breast cancer anticipated to being enrolling in the fourth quarter.
Filing - Sep 10, 2026started Prelude's Phase 1 study of PRT12396, a JAK2V617F mutant selective inhibitor, is now enrolling MF and PV cohorts in parallel.
MF & PV cohorts enrolling in parallel
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.